In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA clears TRIA's acne treatment device for OTC

This article was originally published in The Rose Sheet

Executive Summary

TRIA Beauty is planning a spring 2010 launch for its blue light device designed for home treatment of acne, after receiving over-the-counter clearance from FDA, firm announces. The device will debut on TRIABeauty.com and at select retailers. Firm says its blue light technology is 10 times more powerful than other OTC blue light devices, and that it delivers clear skin faster with shorter treatment times. TRIA cites clinical studies demonstrating the technology "cleared breakouts as quickly and effectively as professional blue light treatments." The company's home-use permanent laser hair-removal device received FDA approval in 2007; it retails for $595 (1"The Rose Sheet" Nov. 9. 2009)

You may also be interested in...



TRIA Enhances Home Hair-Removal Device, Lowers Price In Time For Holidays

TRIA Beauty has upgraded its laser hair-removal device, knocked $200 off the price and launched a multimedia marketing campaign to entice shoppers this holiday season

FDA Slacking In NDI Notification Enforcement; COVID-19 'Is Not An Excuse’ – NPA

In a statement submitted to the Senate Finance Committee, Natural Products Association CEO Dan Fabricant suggests two ways of improving compliance with new dietary ingredient notification requirements at negligible expense to the US FDA.

Finance Watch: Four IPOs In One Week, And Legend Is Year’s Largest So Far

Public Company Edition: Legend Biotech raised $424m in its US public market debut. Also, Pfizer commits up to $500m for equity investments and Allogene capitalizes on ASCO with a $550m offering.

UsernamePublicRestriction

Register

ID1124690

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel